NASDAQ:RGEN - Repligen Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $301.50
  • Forecasted Upside: 79.81 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$167.68
▲ +1.16 (0.70%)

This chart shows the closing price for RGEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Repligen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RGEN

Analyst Price Target is $301.50
▲ +79.81% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Repligen in the last 3 months. The average price target is $301.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 79.81% upside from the last price of $167.68.

This chart shows the closing price for RGEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 polled investment analysts is to buy stock in Repligen. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/12/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/12/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/11/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/9/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/7/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/7/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/6/2022

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/28/2022Craig HallumLower Price Target$286.00 ➝ $274.00Medium
2/18/2022SVB LeerinkLower Price TargetOutperform$275.00 ➝ $250.00Low
12/20/2021SVB LeerinkReiterated RatingBuyHigh
10/29/2021SVB LeerinkBoost Price TargetOutperform$260.00 ➝ $325.00Low
10/14/2021Exane BNP ParibasInitiated CoverageOutperform$330.00High
10/14/2021BNP ParibasInitiated CoverageOutperform$330.00High
9/27/2021Craig HallumBoost Price TargetBuy$258.00 ➝ $368.00High
9/17/2021KeyCorpBoost Price TargetOverweight$255.00 ➝ $335.00High
8/20/2021StephensBoost Price TargetOverweight$255.00 ➝ $290.00Low
7/28/2021Craig HallumBoost Price TargetBuy$251.00 ➝ $258.00High
5/5/2021HC WainwrightBoost Price TargetBuy$225.00 ➝ $240.00Low
4/19/2021HC WainwrightReiterated RatingBuy$168.00 ➝ $225.00Medium
4/12/2021HC WainwrightBoost Price TargetBuy$168.00 ➝ $225.00Low
2/25/2021Craig HallumBoost Price TargetBuy$245.00 ➝ $251.00High
2/25/2021SVB LeerinkBoost Price TargetOutperform$220.00 ➝ $250.00High
1/20/2021Craig HallumBoost Price TargetBuy$229.00 ➝ $245.00High
11/9/2020KeyCorpInitiated CoverageOverweightHigh
8/24/2020HC WainwrightBoost Price TargetBuy$151.00 ➝ $168.00High
6/30/2020HC WainwrightReiterated RatingBuy$143.00 ➝ $151.00High
5/27/2020Stifel NicolausBoost Price TargetPositive ➝ Buy$135.00 ➝ $150.00High
5/7/2020Craig HallumBoost Price TargetBuy$120.00 ➝ $145.00Medium
5/7/2020SVB LeerinkBoost Price TargetOutperform$115.00 ➝ $150.00Medium
5/7/2020HC WainwrightBoost Price TargetBuy$100.00 ➝ $143.00Low
4/2/2020Stifel NicolausLower Price TargetBuy$116.00 ➝ $113.00Low
3/23/2020HC WainwrightLower Price TargetBuy$110.00 ➝ $100.00High
2/21/2020Stifel NicolausBoost Price TargetBuy$105.00 ➝ $116.00Medium
2/21/2020StephensBoost Price TargetOverweight$112.00 ➝ $114.00Medium
1/13/2020HC WainwrightReiterated RatingBuy$110.00High
11/14/2019Stifel NicolausInitiated CoverageBuy$105.00High
11/1/2019First AnalysisUpgradeOutperform ➝ Strong-Buy$107.00 ➝ $110.00High
10/15/2019SVB LeerinkReiterated RatingOutperform$100.00High
8/28/2019First AnalysisBoost Price TargetOutperform$95.00 ➝ $107.00Medium
8/22/2019StephensReiterated RatingOverweight$110.00Medium
8/12/2019HC WainwrightReiterated RatingBuy$110.00Low
8/5/2019Craig HallumBoost Price TargetBuy$80.00 ➝ $108.00High
7/22/2019HC WainwrightUpgradeNeutral ➝ Buy$110.00Low
12/17/2018CL KingUpgradeNeutral ➝ BuyLow
11/12/2018CL KingDowngradeBuy ➝ NeutralMedium
11/5/2018HC WainwrightReiterated RatingHold$60.00Medium
11/2/2018William BlairReiterated RatingOutperformLow
11/2/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$60.00 ➝ $70.00Low
10/4/2018Janney Montgomery ScottReiterated RatingFair Value ➝ BuyHigh
9/26/2018HC WainwrightInitiated CoverageNeutral$49.00Medium
9/24/2018JPMorgan Chase & Co.Boost Price TargetPositive ➝ Overweight$60.00Low
7/20/2018CitigroupBoost Price TargetBuy ➝ Buy$45.00 ➝ $56.00Low
7/10/2018StephensBoost Price TargetOverweight ➝ Average$50.00 ➝ $55.00Low
12/8/2017CitigroupInitiated CoverageBuy ➝ Buy$45.00Medium
12/5/2017JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$42.00High
11/13/2017CL KingInitiated CoverageBuy ➝ Buy$41.00N/A
10/19/2017Jefferies Financial GroupReiterated RatingHold$40.00N/A
10/2/2017First AnalysisUpgradeEqual Weight ➝ Overweight$47.00Medium
9/26/2017StephensReiterated RatingOverweight$50.00High
9/14/2017Jefferies Financial GroupReiterated RatingHold$40.00Medium
7/21/2017William BlairInitiated CoverageOutperform ➝ OutperformLow
(Data available from 7/6/2017 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
12/8/2021
  • 3 very positive mentions
  • 21 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
1/7/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/6/2022
  • 7 very positive mentions
  • 16 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
3/8/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/7/2022
  • 2 very positive mentions
  • 22 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
5/7/2022
  • 1 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/6/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/6/2022

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Repligen logo
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $167.68
Low: $163.30
High: $167.81

50 Day Range

MA: $156.85
Low: $140.68
High: $172.36

52 Week Range

Now: $167.68
Low: $137.21
High: $327.32

Volume

338,270 shs

Average Volume

497,788 shs

Market Capitalization

$9.13 billion

P/E Ratio

66.28

Dividend Yield

N/A

Beta

0.95

Frequently Asked Questions

What sell-side analysts currently cover shares of Repligen?

The following Wall Street research analysts have issued stock ratings on Repligen in the last year: BNP Paribas, Craig Hallum, Exane BNP Paribas, KeyCorp, Stephens, StockNews.com, and SVB Leerink LLC.
View the latest analyst ratings for RGEN.

What is the current price target for Repligen?

0 Wall Street analysts have set twelve-month price targets for Repligen in the last year. Their average twelve-month price target is $301.50, suggesting a possible upside of 79.8%.
View the latest price targets for RGEN.

What is the current consensus analyst rating for Repligen?

Repligen currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RGEN will outperform the market and that investors should add to their positions of Repligen.
View the latest ratings for RGEN.

How do I contact Repligen's investor relations team?

Repligen's physical mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company's listed phone number is (781) 250-0111 and its investor relations email address is [email protected] The official website for Repligen is www.repligen.com. Learn More about contacing Repligen investor relations.